Skip to main content
SpringerLink
Log in

OnabotulinumtoxinA for Refractory Headache

  • Chapter
Peripheral Interventional Management in Headache

Part of the book series: Headache ((HEAD))

  • 541 Accesses

Abstract

Refractory headaches, also known as treatment-resistant headaches, are a poorly defined and heterogeneous group of headache disorders. Chronic migraine is the most common clinical subtype of refractory headache. OnabotulinumtoxinA is widely used for the prophylactic treatment of chronic migraine. However, its effect on other refractory headaches, including chronic cluster headache and medication overuse headache, has not been fully clarified. This chapter reviews the pharmacological properties, efficacy, and tolerability of onabotulinumtoxinA, with special focus on its potential role in the treatment of refractory chronic migraine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache. 2010;50(9):1499–506.

    Article  Google Scholar 

  2. Schulman EA, Peterlin BL, Lake AE 3rd, Lipton RB, Hanlon A, Siegel S, Levin M, Goadsby PJ, Markley HG. Defining refractory migraine: results of the RHSIS Survey of American Headache Society members. Headache. 2009;49(4):509–18.

    Article  Google Scholar 

  3. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

    Article  Google Scholar 

  4. Whitcup SM, Turkel CC, DeGryse RE, Brin MF. Development of onabotulinumtoxinA for chronic migraine. Ann N Y Acad Sci. 2014;1329:67–80.

    Article  CAS  Google Scholar 

  5. Butera C, Colombo B, Bianchi F, Cursi M, Messina R, Amadio S, Guerriero R, Comi G, DelCarro U. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A? Neurol Sci. 2016;37(10):1701–6.

    Article  Google Scholar 

  6. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455–64.

    Article  CAS  Google Scholar 

  7. Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, Reed ML, Buse DC. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012;13(8):615–24.

    Article  Google Scholar 

  8. Frampton JE, Silberstein S. OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs. 2018;78(5):589–600.

    Article  CAS  Google Scholar 

  9. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.

    Article  CAS  Google Scholar 

  10. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.

    Article  CAS  Google Scholar 

  11. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36.

    Article  Google Scholar 

  12. Oterino A, Ramón C, Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. J Headache Pain. 2011;12(2):235–8.

    Article  CAS  Google Scholar 

  13. Gooriah R, Buture A, Ahmed F. Evidence-based treatments for cluster headache. Ther Clin Risk Manag. 2015;11:1687–96.

    Article  CAS  Google Scholar 

  14. Sostak P, Krause P, Förderreuther S, Reinisch V, Straube A. Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain. 2007;8(4):236–41.

    Article  CAS  Google Scholar 

  15. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406–18.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hartford Healthcare Headache Center, University of Connecticut School of Medicine, West Hartford, CT, USA

    Abigail L. Chua

  2. BIDMC Comprehensive Headache Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Sait Ashina

  3. Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, NY, USA

    Richard Lipton

Authors
  1. Abigail L. Chua
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sait Ashina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abigail L. Chua .

Editor information

Editors and Affiliations

  1. School of Medicine, Mersin University, Mersin, Turkey

    Aynur Özge

  2. Istanbul University Cerrahpasa Medical Faculty, Neurology Department, Istanbul, Turkey

    Derya Uludüz

  3. Department of Neurology, Gulhane Medical Faculty, Ankara, Turkey

    Ömer Karadaş

  4. Medical Faculty, Gazi University Medical Faculty, Ankara, Turkey

    Hayrunnisa Bolay

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Cite this chapter

Chua, A.L., Ashina, S., Lipton, R. (2019). OnabotulinumtoxinA for Refractory Headache. In: Özge, A., Uludüz, D., Karadaş, Ö., Bolay, H. (eds) Peripheral Interventional Management in Headache. Headache. Springer, Cham. https://doi.org/10.1007/978-3-030-10853-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-10853-3_6

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-10852-6

  • Online ISBN: 978-3-030-10853-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation